CAD enters digital mammography
Computer-aided detection software developed by R2 Technology can now be marketed as an integral part of the GE Senographe 2000D full-field digital mammography system, following FDA approval. This is the latest step in R2's pioneering efforts to make CAD
Computer-aided detection software developed by R2 Technology can now be marketed as an integral part of the GE Senographe 2000D full-field digital mammography system, following FDA approval. This is the latest step in R2's pioneering efforts to make CAD a routine part of medical practice. The FDA approved the company's ImageChecker, a stand-alone CAD workstation, in 1998 for use with film-based screening mammography. Three years later the FDA expanded approval to include its use with diagnostic mammograms. R2 has shipped more than 400 film and digital-based systems worldwide. More than three million women have had their mammograms interpreted with the aid of the ImageChecker CAD system. Nearly 300 Senographe 2000D systems have been installed in the U.S. All are upgradable to R2's CAD technology.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
